172 Results

People

  1. Motzer
    Motzer
  2. Abrey
    Abrey
  3. De Angelis
    De Angelis
  4. Riely
    Riely
  5. Abou-Alfa
    Abou-Alfa
  6. Kelly
    Kelly
  7. Scher
    Scher
  8. Drilon
    Drilon
  9. Feldman
    Feldman
  10. Ginsberg
    Ginsberg

Groups

  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)
  7. Biostatistics Service (27)
  8. Thoracic Oncology (19)
  9. Division of Subspecialty Medicine (18)
  10. GSK Faculty (18)
  1. "hypophosphatemia"
Formats
  1. Journal Article (160)
  2. Review (7)
  3. Research Letter (2)
  4. Book Section (1)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Department of Medicine (125)
  2. Solid Tumor Oncology Division (83)
  3. Hematologic Malignancies, Division of (43)
  4. Center for Hematologic Malignancies (34)
  5. Genitourinary Oncology Service (31)
  6. Epidemiology and Biostatistics (28)

More Groups

People
  1. Robert Motzer (18)
  2. Lauren Abrey (9)
  3. Lisa De Angelis (8)
  4. Gregory Riely (7)
  5. Ghassan Abou-Alfa (6)
  6. Howard Scher (6)

More People

Years
  1. 2025 (8)
  2. 2024 (13)
  3. 2023 (13)
  4. 2022 (7)
  5. 2021 (4)
  6. 2020 (21)

More Years

Publications
  1. Lancet Oncology (16)
  2. Cancer (11)
  3. Clinical Cancer Research (11)
  4. Journal of Clinical Oncology (10)
  5. New England Journal of Medicine (10)
  6. Neuro-Oncology (6)

More Publications

Publishers
  1. Elsevier Science, Inc. (25)
  2. Elsevier Inc. (19)
  3. American Association for Cancer Research (12)
  4. Wiley Blackwell (12)
  5. Oxford University Press (11)
  6. Springer (11)

More Publishers

Results (172)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients
    Journal Article

    Lee, E. Q.; Kaley, T. J.; Duda, D. G.; Schiff, D.; Lassman, A. B.; Wong, E. T.; Mikkelsen, T.; Purow, B. W.; Muzikansky, A.; Ancukiewicz, M.; more...
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Phase I/II trial of paclitaxel with ifosfamide followed by high-dose paclitaxel, ifosfamide, and carboplatin (TI-TIC) with autologous stem cell reinfusion for salvage treatment of germ cell tumors
    Journal Article

    Feldman, D. R.; Glezerman, I.; Patil, S.; Van Alstine, L.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M.; Reich, L.; more...
    Clinical Genitourinary Cancer (2015)

    Fulltext@MSK | Save
  • Blinatumomab: A first-in-class bispecific T-cell engager for precursor B-cell acute lymphoblastic leukemia
    Journal Article

    Buie, L. W.; Pecoraro, J. J.; Horvat, T. Z.; Daley, R. J.
    Annals of Pharmacotherapy (2015)

    Fulltext@MSK | Save
  • Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: A Children's Oncology Group report
    Journal Article

    Trippett, T. M.; Schwartz, C. L.; Guillerman, R. P.; Gamis, A. S.; Gardner, S.; Hogan, S.; London, W. B.; Chen, L.; de Alarcon, P.
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation
    Journal Article

    Straus, D. J.; Hamlin, P. A.; Matasar, M. J.; Lia Palomba, M.; Drullinsky, P. R.; Zelenetz, A. D.; Gerecitano, J. F.; Noy, A.; Hamilton, A. M.; Elstrom, R.; more...
    British Journal of Haematology (2015)

    Fulltext@MSK | Save
  • Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
    Journal Article

    Kaley, T. J.; Wen, P.; Schiff, D.; Ligon, K.; Haidar, S.; Karimi, S.; Lassman, A. B.; Nolan, C. P.; De Angelis, L. M.; Gavrilovic, I.; more...
    Neuro-Oncology (2014)

    Fulltext@MSK | Save
  • Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): Results from the dose-finding portion of a phase 1/2 study
    Journal Article

    Gadgeel, S. M.; Gandhi, L.; Riely, G. J.; Chiappori, A. A.; West, H. L.; Azada, M. C.; Morcos, P. N.; Lee, R. M.; Garcia, L.; Yu, L.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A non-randomised, phase 1b study
    Journal Article

    Younes, A.; Thieblemont, C.; Morschhauser, F.; Flinn, I.; Friedberg, J. W.; Amorim, S.; Hivert, B.; Westin, J.; Vermeulen, J.; Bandyopadhyay, N.; more...
    Lancet Oncology (2014)

    Fulltext@MSK | Save
  • Effects of tyrosine kinase inhibition on bone metabolism: Untargeted consequences of targeted therapies
    Journal Article

    Aleman, J. O.; Farooki, A.; Girotra, M.
    Endocrine-Related Cancer (2014)

    Fulltext@MSK | Save
  • Drug nephropathies
    Book Section

    Glezerman, I. G.
    In Finkel, K. W.; Howard, S. C. (Eds.) Renal Disease in Cancer Patients (2014)

    Fulltext@MSK | Save